Home LiteratureArticle Details
PMID: 7474108 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period.

Journal of virology ·Vol. 69 ·No. 11 ·1995-11-00 ·Pages 6911-6

Lukashov VV, Kuiken CL, Goudsmit J

Abstract

The antigenic diversity threshold theory predicts that antigenic sites of human immunodeficiency virus type 1, such as the V3 region of the external glycoprotein gp120, evolve more rapidly during the symptom-free period in individuals progressing to AIDS than in those who remain asymptomatic for a long time. To test this hypothesis, genomic RNA sequences were obtained from the sera of 44 individuals at seroconversion and 5 years later. The mean number of nonsynonymous nucleotide substitutions in the V3 region of the viruses circulating in 31 nonprogressors (1.1 x 10(-2) +/- 0.1 x 10(-2) per site per year) was higher than the corresponding value for 13 progressors (0.66 x 10(-2) +/- 0.1 x 10(-2) per site per year) (P < 0.01), while no difference between the mean numbers of synonymous substitutions in the two groups was seen (0.37 x 10(-2) +/- 0.1 x 10(-2) and 0.51 x 10(-2) +/- 0.2 x 10(-2) per site per year for nonprogressors and progressors, respectively; P > 0.1). The mean ratios of synonymous nucleotide p distance to nonsynonymous p distance were 0.35 for nonprogressors and 0.62 for progressors. The number of nonsynonymous substitutions was not associated with virus load or virus phenotype, which are established predictors of disease progression, but correlated strongly with the duration of the immunocompetent period (r2 = 0.41; P = 0.001). This indicates that there is no causative relationship between intrahost evolution and CD4+ cell decline. Our data suggest that intrahost evolution in human immunodeficiency virus type 1 infection is driven by selective forces, the strength of which is related to the duration of the immunocompetent period.

MeSH Terms
Acquired Immunodeficiency Syndrome/immunology Antigenic Variation Biological Evolution Cohort Studies Disease Progression HIV Envelope Protein gp120/genetics HIV Seropositivity/immunology HIV-1/genetics,immunology Homosexuality, Male Humans Immunocompetence Male Phenotype Phylogeny Prospective Studies Time Factors
Chemicals
HIV Envelope Protein gp120
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Lukashov V V
Human Retrovirus Laboratory, University of Amsterdam, The Netherlands.
Kuiken C L
Goudsmit J
References (49)
49 references, click to expand
  1. Estimation of evolutionary distances between homologous nucleotide sequences.
    Proc Natl Acad Sci U S A. 1981 Jan;78(1):454-8 PMID: 6165991
  2. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.
    AIDS. 1995 May;9(5):435-9 PMID: 7639968
  3. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6 PMID: 2450351
  4. Biologic features of HIV-1 that correlate with virulence in the host.
    Science. 1988 Apr 1;240(4848):80-2 PMID: 2832945
  5. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9 PMID: 2452443
  6. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  7. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  8. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
    Lancet. 1989 May 6;1(8645):983-5 PMID: 2565516
  9. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.
    Cell. 1989 Sep 8;58(5):901-10 PMID: 2550139
  10. Selection of antigenic variants of foot-and-mouth disease virus in the absence of antibodies, as revealed by an in situ assay.
    J Gen Virol. 1989 Dec;70 ( Pt 12):3281-9 PMID: 2481712
  11. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.
    J Virol. 1990 Feb;64(2):864-72 PMID: 2296085
  12. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself.
    J Exp Med. 1990 Feb 1;171(2):571-6 PMID: 1689366
  13. Rapid and simple method for purification of nucleic acids.
    J Clin Microbiol. 1990 Mar;28(3):495-503 PMID: 1691208
  14. The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease.
    AIDS. 1990 Nov;4(11):1095-103 PMID: 2282182
  15. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual.
    J Virol. 1991 Apr;65(4):1968-75 PMID: 2002552
  16. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.
    Virology. 1991 Apr;181(2):481-9 PMID: 2014634
  17. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.
    J Virol. 1991 Nov;65(11):5782-9 PMID: 1920616
  18. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution.
    Virology. 1991 Nov;185(1):195-205 PMID: 1656585
  19. Antigenic diversity thresholds and the development of AIDS.
    Science. 1991 Nov 15;254(5034):963-9 PMID: 1683006
  20. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.
    J Virol. 1992 Feb;66(2):757-65 PMID: 1731110
  21. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
    J Virol. 1992 Mar;66(3):1354-60 PMID: 1738194
  22. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.
    AIDS. 1992 Jan;6(1):49-54 PMID: 1543566
  23. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant.
    Science. 1992 Jan 17;255(5042):333-6 PMID: 1372448
  24. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.
    J Virol. 1992 May;66(5):3183-7 PMID: 1560543
  25. Sequence ordinations: a multivariate analysis approach to analysing large sequence data sets.
    Comput Appl Biosci. 1992 Feb;8(1):15-22 PMID: 1568121
  26. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient.
    Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4835-9 PMID: 1594583
  27. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype.
    J Virol. 1992 Jul;66(7):4622-7 PMID: 1602564
  28. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.
    J Virol. 1992 Nov;66(11):6547-54 PMID: 1404602
  29. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.
    J Virol. 1992 Nov;66(11):6777-80 PMID: 1404617
  30. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease.
    Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10247-51 PMID: 1438212
  31. Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1.
    AIDS Res Hum Retroviruses. 1992 Nov;8(11):1897-908 PMID: 1489578
  32. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.
    Science. 1993 Mar 19;259(5102):1749-54 PMID: 8096089
  33. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.
    Ann Intern Med. 1993 May 1;118(9):681-8 PMID: 8096374
  34. Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection.
    J Virol. 1993 Oct;67(10):6071-9 PMID: 7690417
  35. New observations on antigenic diversification of RNA viruses. Antigenic variation is not dependent on immune selection.
    J Gen Virol. 1993 Oct;74 ( Pt 10):2039-45 PMID: 7691985
  36. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.
    J Virol. 1993 Nov;67(11):6897-902 PMID: 8411395
  37. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11518-22 PMID: 7505441
  38. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Virology. 1994 Mar;199(2):431-8 PMID: 8122371
  39. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Virology. 1994 Jun;201(2):285-93 PMID: 7514319
  40. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences.
    J Virol. 1994 Jul;68(7):4643-49 PMID: 8207838
  41. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
    J Virol. 1994 Sep;68(9):6006-13 PMID: 8057475
  42. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays.
    J Virol. 1994 Oct;68(10):6672-83 PMID: 8084001
  43. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
    Virology. 1994 Oct;204(1):223-33 PMID: 7916514
  44. A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients.
    J Immunol. 1994 Oct 15;153(8):3822-30 PMID: 7523505
  45. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes.
    J Virol Methods. 1994 Sep;49(2):157-67 PMID: 7822457
  46. Differences in human immunodeficiency virus type 1 V3 sequences from patients with and without AIDS dementia complex.
    J Gen Virol. 1995 Jan;76 ( Pt 1):175-80 PMID: 7844529
  47. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.
    J Exp Med. 1995 Apr 1;181(4):1365-72 PMID: 7699324
  48. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
    J Infect Dis. 1995 Apr;171(4):811-21 PMID: 7706807
  49. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.
    Science. 1986 Jun 20;232(4757):1548-53 PMID: 3012778
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.69.11.6911-6916.1995
Published
1995-11-00
Pages
6911-6
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC189608
Subset
IM
External Links
PubMed source DOI: 10.1128/JVI.69.11.6911-6916.1995 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2